Cargando…

Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure

The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from ant...

Descripción completa

Detalles Bibliográficos
Autores principales: XUN, YUN-HAO, SHI, JUN-PING, LI, CHUN-QING, LI, DAN, SHI, WEI-ZHEN, PAN, QING-CHUN, GUO, JIAN-CHUN, ZANG, GUO-QING
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020485/
https://www.ncbi.nlm.nih.gov/pubmed/24573151
http://dx.doi.org/10.3892/mmr.2014.1983
_version_ 1782316075515379712
author XUN, YUN-HAO
SHI, JUN-PING
LI, CHUN-QING
LI, DAN
SHI, WEI-ZHEN
PAN, QING-CHUN
GUO, JIAN-CHUN
ZANG, GUO-QING
author_facet XUN, YUN-HAO
SHI, JUN-PING
LI, CHUN-QING
LI, DAN
SHI, WEI-ZHEN
PAN, QING-CHUN
GUO, JIAN-CHUN
ZANG, GUO-QING
author_sort XUN, YUN-HAO
collection PubMed
description The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from antivirals. A total of 77 patients with ACHBLF of mean age 46 years, 82% male, with 58.4% receiving antivirals, were recruited for this study. The Δ scores for MELDs were defined as the changes one week after admission. Thirty-eight (49%) patients (22 treated with antivirals) died within three months. The mean MELD and ΔMELD scores of the survival group were 19.5±4.4 and 0.2±3.7 respectively, and those of the mortality group were 23.5±5.5 and 7.9±6, respectively. The area under the receiver operating characteristic curve (AUC) for MELD, integrated MELD (iMELD), MELD with the addition of serum sodium (MELD-Na), updated MELD (upMELD), MELD excluding the international normalized ratio (INR; MELD-XI), United Kingdom MELD (UKMELD) and their Δ scores were 0.72, 0.81, 0.77, 0.69, 0.65, 0.77 and 0.86, 0.83, 0.83, 0.82, 0.79 and 0.79, respectively. iMELD and MELD-Na significantly improved the accuracy of MELD (P<0.05). A cut-off value of 41.5 for the iMELD score can prognose 71% of mortalities with a specificity of 85%. In each pair of models, the Δ score was superior to its counterpart, particularly when applied to patients with MELD ≤30. Decreased accuracy was observed for all models in the subset of patients treated with antivirals, although their baseline characteristics were comparable to those of untreated patients, while iMELD, MELD-Na and respective Δ models remained superior with regard to the predictability. The iMELD and MELD-Na models predicted three-month mortality more accurately, while the Δ models were superior to their counterparts when MELD ≤30; however, their performance was altered by antivirals, and thus requires optimization.
format Online
Article
Text
id pubmed-4020485
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-40204852014-05-14 Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure XUN, YUN-HAO SHI, JUN-PING LI, CHUN-QING LI, DAN SHI, WEI-ZHEN PAN, QING-CHUN GUO, JIAN-CHUN ZANG, GUO-QING Mol Med Rep Articles The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from antivirals. A total of 77 patients with ACHBLF of mean age 46 years, 82% male, with 58.4% receiving antivirals, were recruited for this study. The Δ scores for MELDs were defined as the changes one week after admission. Thirty-eight (49%) patients (22 treated with antivirals) died within three months. The mean MELD and ΔMELD scores of the survival group were 19.5±4.4 and 0.2±3.7 respectively, and those of the mortality group were 23.5±5.5 and 7.9±6, respectively. The area under the receiver operating characteristic curve (AUC) for MELD, integrated MELD (iMELD), MELD with the addition of serum sodium (MELD-Na), updated MELD (upMELD), MELD excluding the international normalized ratio (INR; MELD-XI), United Kingdom MELD (UKMELD) and their Δ scores were 0.72, 0.81, 0.77, 0.69, 0.65, 0.77 and 0.86, 0.83, 0.83, 0.82, 0.79 and 0.79, respectively. iMELD and MELD-Na significantly improved the accuracy of MELD (P<0.05). A cut-off value of 41.5 for the iMELD score can prognose 71% of mortalities with a specificity of 85%. In each pair of models, the Δ score was superior to its counterpart, particularly when applied to patients with MELD ≤30. Decreased accuracy was observed for all models in the subset of patients treated with antivirals, although their baseline characteristics were comparable to those of untreated patients, while iMELD, MELD-Na and respective Δ models remained superior with regard to the predictability. The iMELD and MELD-Na models predicted three-month mortality more accurately, while the Δ models were superior to their counterparts when MELD ≤30; however, their performance was altered by antivirals, and thus requires optimization. D.A. Spandidos 2014-05 2014-02-25 /pmc/articles/PMC4020485/ /pubmed/24573151 http://dx.doi.org/10.3892/mmr.2014.1983 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
XUN, YUN-HAO
SHI, JUN-PING
LI, CHUN-QING
LI, DAN
SHI, WEI-ZHEN
PAN, QING-CHUN
GUO, JIAN-CHUN
ZANG, GUO-QING
Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
title Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
title_full Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
title_fullStr Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
title_full_unstemmed Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
title_short Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
title_sort prognostic performance of a series of model for end-stage liver disease and respective δ scores in patients with hepatitis b acute-on-chronic liver failure
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020485/
https://www.ncbi.nlm.nih.gov/pubmed/24573151
http://dx.doi.org/10.3892/mmr.2014.1983
work_keys_str_mv AT xunyunhao prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT shijunping prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT lichunqing prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT lidan prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT shiweizhen prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT panqingchun prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT guojianchun prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure
AT zangguoqing prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure